- Home
- IMXI vs CELC Comparison
IMXI vs CELC Comparison
Compare IMXI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- CELC
- Stock Information
- Founded
- IMXI N/A
- CELC 2011
- Country
- IMXI United States
- CELC United States
- Employees
- IMXI N/A
- CELC 55
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- CELC Medical Specialities
- Sector
- IMXI Technology
- CELC Health Care
- Exchange
- IMXI Nasdaq
- CELC Nasdaq
- Market Cap
- IMXI 649.7M
- CELC 489.7M
- IPO Year
- IMXI N/A
- CELC 2017
- Fundamental
- Price
- IMXI $21.32
- CELC $13.19
- Analyst Decision
- IMXI Buy
- CELC Strong Buy
- Analyst Count
- IMXI 6
- CELC 6
- Target Price
- IMXI $27.50
- CELC $29.17
- AVG Volume (30 Days)
- IMXI 369.2K
- CELC 283.3K
- Earning Date
- IMXI 11-08-2024
- CELC 11-14-2024
- Dividend Yield
- IMXI N/A
- CELC N/A
- EPS Growth
- IMXI 21.49
- CELC N/A
- EPS
- IMXI 1.80
- CELC N/A
- Revenue
- IMXI $665,673,000.00
- CELC N/A
- Revenue This Year
- IMXI $3.27
- CELC N/A
- Revenue Next Year
- IMXI $5.53
- CELC N/A
- P/E Ratio
- IMXI $11.87
- CELC N/A
- Revenue Growth
- IMXI 3.79
- CELC N/A
- 52 Week Low
- IMXI $16.17
- CELC $11.51
- 52 Week High
- IMXI $23.28
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- IMXI 70.91
- CELC 37.29
- Support Level
- IMXI $20.55
- CELC $12.08
- Resistance Level
- IMXI $22.37
- CELC $16.14
- Average True Range (ATR)
- IMXI 0.70
- CELC 0.93
- MACD
- IMXI 0.12
- CELC -0.25
- Stochastic Oscillator
- IMXI 78.96
- CELC 33.38
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.